Akkermansia muciniphila in Central Nervous System Disorders: Mechanisms, Controversies, and Therapeutic Potential

Area of Science:

• Microbiology
• Neuroscience
• Gastroenterology

Background:

• Akkermansans muciniphila (A. muciniphila) is a mucus-degrading bacterium with known links to metabolic diseases.
• Emerging research implicates A. muciniphila in central nervous system (CNS) disorders through the microbiota-gut-brain axis (MGBA).

Purpose of the Study:

• To review the complex relationship between A. muciniphila and CNS disorders.
• To highlight the bacterium's dual roles in neuroprotection and pathogenesis.
• To discuss its potential as a diagnostic biomarker and therapeutic target.

Main Methods:

• Literature review of studies investigating A. muciniphila and CNS disorders.
• Analysis of proposed mechanisms: immunomodulation, metabolic regulation, and barrier reinforcement.
• Examination of context-dependent effects in various neurological conditions.

Main Results:

• A. muciniphila demonstrates beneficial effects in Alzheimer's disease, stroke, and depression.
• Its role in multiple sclerosis and Parkinson's disease is context-dependent and requires further investigation.
• Key mechanisms involve modulating immunity, metabolism, and reinforcing biological barriers.

Conclusions:

• A. muciniphila exhibits a complex, dual role in CNS disorders, acting as both neuroprotective and potentially pathogenic.
• Further research is crucial to establish causality and therapeutic applications.
• The bacterium holds promise as a biomarker and a target for next-generation probiotics in managing CNS diseases.